Table 3: Synopsis of the significant alterations in the immune system before (1), during (2), at the end (3), and 15 minutes after hemodialysis (4) of Tables 2 and 4.

FriedmanWilcoxon signed-rank test
Period sample1 to 41 and 21 and 31 and 42 and 32 and 41 and 4

Natural killer cells0.0280.0180.5240.5240.1210.0180.389
Natural killer T cells0.0030.0030.080.1940.2680.0580.233
Double-negative T cells<0.001<0.0010.005<0.0010.0770.5240.244
CD4+ T cells0.001<0.0010.1210.1070.1510.0950.599
CD8+ T cells0.010.0050.0350.0550.2080.9780.208
CD25+ T cells0.0060.0420.0180.0260.2290.2290.978
CD4+ HLA-DR+ T cells0.0390.0020.4540.5610.1690.1730.303
CD8+ HLA-DR+ T cells0.0160.0010.4320.1690.890.1510.389
CD8+ naive T cells0.165
CD8+ effector cells0.0130.0070.8040.5610.1210.0730.524
CD8+ CCR5+ T cells0.0010.0410.4540.1690.0830.0070.208
Regulatory T cells0.0060.0050.0030.0030.5840.3590.588
HLA-DR+ Tregs0.050.8470.1510.0050.1690.0550.083
Complement CP0.0460.0730.8470.3590.1210.0030.296
Complement AP0.0170.1530.030.6790.4540.0730.003
TGFβ<0.001<0.0010.720.359<0.001<0.0010.524
sCD300.0040.0040.4540.5610.107<0.0010.326
Eosinophils0.062
Neutrophils0.744

Blood samples: before (1), after one hour (2), at the end (3), and 15 minutes after the end of HD (4). Statistical analysis with the Friedman test and the post hoc Wilcoxon signed-rank test. values ≤ 0.003 were considered to be significant according to Bonferroni. CP: complement activation, classical pathway; AP: complement activation, alternative pathway. Not tested due to a nonsignificant Friedman test.